Better Health for All
20
QIAGEN's core business focuses on molecular diagnostics and life sciences, aiming to advance science and improve patient outcomes globally by developing solutions to understand, treat, and prevent diseases such as TB, COVID-19, HPV, and cancer. Over 100 million QuantiFERON-TB Gold Plus tests have been distributed across 130 countries.
1
The company played a key role in global health crises, achieving a 50-fold increase in production capacity of reagents for COVID tests in 2020
2
and coordinating responses to outbreaks like the 2024 MPOX Clade 1.
3
QIAGEN offers a single lowest global price for its products in Low and Middle-Income Countries (LMICs) and WHO-identified high-burden countries, along with need-based donations.
4
It prioritizes equitable distribution of tests, aiming to leave no country or region behind, and supports vulnerable populations through initiatives like TB education in First Nation communities and HPV screening in El Salvador.
5
The company invests significantly in innovation, recognized as a leading funder of TB diagnostics research and investing over $500,000 in pediatric TB research in 2021.
6
QIAGEN maintains strong data protection based on ISO 27001, with approximately 85% of staff completing cybersecurity training.
7
Clinical trials adhere to ethical standards including the Declaration of Helsinki, IRB approval, informed consent, and public registration on clinicaltrials.gov.
8
Employee mental health is supported through a global Employee Assistance Program and mental health first aiders.
9
The company had 7 product recalls in 2023, 6 in 2022, and 6 in 2021
10
, but 0 FDA Class I recalls
11
, and achieved 90-100% customer reach for recalls.
12
QIAGEN has reduced Scope 1 and 2 emissions by 15%
13
and reduced plastic use by 25 tons in 2024.
14
Fair Money & Economic Opportunity
0
QIAGEN N.V. operates in the biotechnology sector and does not engage in financial services, lending, or microfinance.
1
The company's core business focuses on providing molecular technologies and products for life sciences and molecular diagnostics.
2
Therefore, all KPIs related to fair money and economic opportunity are not applicable.
Fair Pay & Worker Respect
20
The company reported a 0.50% pay gap in 2023.
1
It achieved a 100 score in the Corporate Equality Index for fostering gender diversity
2
and had women in 36% of leadership roles in 2023, up from 35% in 2022, with a goal of 40% by 2027.
3
In 2023, lost working cases were reduced by 63% compared to 2022.
4
QIAGEN also received a 5-star ranking in America's Greatest Workplaces 2023, noting high retention rates.
5
Fair Trade & Ethical Sourcing
-30
QIAGEN conducts on-site quality audits for critical direct suppliers at least every three years, with over 20 site visits anticipated in 2024.
1
Beginning in 2024, ESG-related topics will be incorporated into procedures evaluating quality processes.
2
In 2023, QIAGEN updated its Supplier Code of Conduct, which suppliers must agree to as a precondition for contractual relationships.
3
As of 2023, 80% of QIAGEN’s suppliers, measured by spend, have committed to achieving at least one environmental and one social goal.
4
Acceptance of a Purchase Order automatically signifies acceptance of the Code of Conduct.
5
All procurement employees completed mandatory training on the revised Code.
6
A Human Rights Committee was established in 2023 to ensure ethical standards in operations and the supply chain.
7
The company conducts annual due diligence for conflict minerals and disclosed findings to the SEC for the calendar year ending December 31, 2023, on May 31, 2024.
8
Honest & Fair Business
10
QIAGEN has established the QIAintegrity Line, an independent, impartial, and confidential digital reporting system for employees and third parties to report violations of laws, internal rules, and the Corporate Code of Conduct and Ethics.
1
The company also maintains a Corporate Code of Conduct and Ethics and an updated Supplier Code of Conduct (2023) that requires suppliers to adhere to high standards in legal compliance.
2
QIAGEN enforces an ethical supplier policy, achieving 80% supplier compliance in 2023.
3
Furthermore, a Human Rights Committee has been established to uphold ethical standards across its operations and supply chain.
4
Kind to Animals
40
QIAGEN explicitly states that it does not conduct any animal testing or related research activities
1
, indicating an absolute global ban on animal testing for its own operations
2
. This means non-animal platforms replace every in vivo test within the company, and no live animals are used or counted by QIAGEN. However, the company acknowledges that some raw materials are sourced from suppliers who may engage in animal testing
3
. To address this, QIAGEN updated its Supplier Code of Conduct in 2023
4
, requiring suppliers to adhere to guidelines set by international organizations such as the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC)
5
.
No War, No Weapons
-30
QIAGEN's core business is health and scientific research, with no direct involvement in arms manufacturing. The company has engaged in minor defense contracts for non-lethal, health-oriented products like diagnostic tests and reagents
1
, with confirmed obligations totaling approximately $4.8 million
2
. This represents less than 1% of its 2024 annual sales of $1.98 billion
3
. QIAGEN is not active in any direct lobbying activities
4
. The company is guided by the UN Guiding Principles on Business and Human Rights
5
, with its Human Rights Committee performing annual risk analysis
6
. Annual human rights due diligence, including for conflict minerals from high-risk areas, is conducted, with findings disclosed to the U.S. Securities and Exchange Commission
7
. QIAGEN explicitly states 'Not applicable' for involvement in controversial weapons
8
and does not tolerate the misuse of its products for mass screening or surveillance of ethnic minorities
9
. Annual risk assessments cover existing suppliers
10
, and the company expects all suppliers to comply with its Supplier Code of Conduct, which includes human rights and labor rights requirements
11
.
Planet-Friendly Business
-30
QIAGEN's total corporate carbon footprint in 2022 was 329,524 tCO2e, representing a 13.5% reduction compared to the previous year.
1
The company's carbon emissions targets, including a 1.5°C aligned Scope 1 and 2 target, were validated by the Science Based Targets initiative (SBTi) in 2023.
2
In 2024, 40% of total energy consumption was sourced from renewables.
3
Water withdrawal in 2022 was 0.05532 m³ per $1M Net Sales, and no sites were identified as being in or near areas of high water stress in 2024.
4
More than a third of main locations have achieved green building certifications, including LEED Gold, Silver, and BREEAM, with a newly leased site being LEED Platinum certified.
5
The company recycled 53% of its total waste in 2024.
6
In 2024, 32% of capital expenditure was aligned with the EU Taxonomy.
7
However, QIAGEN did not finance GHG removals or mitigation projects through carbon credits.
8
The company used 3.8% of reused or recycled secondary materials in product manufacturing and packaging.
9
A 16.5% reduction in transportation packaging was achieved in 2022 compared to 2021.
10
QIAGEN has integrated climate-related risks and opportunities into its enterprise risk management framework, providing a TCFD Index.
11
Climate risk assessments in 2024 utilized SSP5-/RCP8.5 and 1.5°C aligned bespoke climate transition scenarios.
12
Life Cycle Assessments were conducted for the QIAamp DNA Mini Kit in 2021 and the QIAstat Dx Analyzer in 2024.
13
Respect for Cultures & Communities
60
QIAGEN engages in over 50 public health partnerships and numerous joint healthcare projects in more than 30 countries.
1
These include collaborations with the Pasteur Network, Malawi-Liverpool Wellcome Trust, Basic Health International, and the non-profit Ohkomi Forensics for an Indigenous-owned DNA database.
2
The company reports zero cultural appropriation incidents.
3
A global, publicly accessible QIAGEN Integrity Line is available for all persons or groups affected by human rights or environmental risks or violations within QIAGEN’s business or supply chains.
4
QIAGEN supports the creation of an Indigenous-owned DNA database, contributing to cultural heritage preservation.
5
Online training is provided to employees in nine languages, and a digital reporting system is available in 19 languages.
6
The company's proactive engagement on culturally sensitive issues, such as the Indigenous DNA database, and zero reported cultural appropriation incidents indicate a proactive approach to cultural incident response.
Safe & Smart Tech
-50
In October 2024, a lawsuit was filed against Verogen Inc., acquired by QIAGEN in 2023, alleging the unauthorized disclosure of genetic information for nearly 2 million people.
1
This incident also led to alleged violations of genetic-privacy laws in multiple states, indicating significant compliance gaps and an instance of unauthorized data use.
2
User data control is basic, allowing users to unsubscribe from investor alerts and revoke consent.
3
While the company states a general principle of collecting only necessary data, marketing data is retained for up to 3 years.
4
Positively, approximately 85% of employees completed mandatory cybersecurity awareness training, which includes regular phishing simulations.
5
Zero Waste & Sustainable Products
-40
QIAGEN recycled 53% of its total waste in 2024.
1
The estimated recyclability of its products is over 70%, based on an analysis of the QIAamp DNA Mini Kit.
2
In 2024, 3.8% of total materials used for product manufacture, including packaging and services, were reused or recycled secondary materials.
3
The company achieved a 16.5% decrease in plastic usage in 2022.
4
and removed over 25 tons of plastic from products and packaging in 2024.
5
QIAGEN has adopted a 'replace – reduce – reuse – recycle – recover' approach, is developing circular design guidelines, and conducted a circularity analysis of the QIAamp DNA Mini Kit. Hazardous waste is managed with internal controls to ensure compliant storage, removal, and disposal, with 5% of hazardous waste recycled in 2024.
6
QIAGEN had a target to reduce plastic by 20 tons in 2024 and aims for over 25 tons in 2025.
7
The company provides comprehensive customer waste education through product labeling, recycling instructions, practical guides, and live Q-rious shows.